About hutchmed china - HCM
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.
HCM At a Glance
HUTCHMED (China) Ltd.
Cheung Kong Center
Hong Kong,
| Phone | 852-2121-8200 | Revenue | 838.00M | |
| Industry | Pharmaceuticals: Major | Net Income | 100.78M | |
| Sector | Health Technology | 2023 Sales Growth | 96.525% | |
| Fiscal Year-end | 12 / 2024 | Employees | 1,988 | |
| View SEC Filings |
HCM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 31.24 |
| Price to Sales Ratio | 3.757 |
| Price to Book Ratio | 4.32 |
| Price to Cash Flow Ratio | 14.359 |
| Enterprise Value to EBITDA | 92.482 |
| Enterprise Value to Sales | 2.817 |
| Total Debt to Enterprise Value | 0.036 |
HCM Efficiency
| Revenue/Employee | 421,528.672 |
| Income Per Employee | 50,694.165 |
| Receivables Turnover | 5.57 |
| Total Asset Turnover | 0.726 |
HCM Liquidity
| Current Ratio | 2.722 |
| Quick Ratio | 2.597 |
| Cash Ratio | 2.199 |
HCM Profitability
| Gross Margin | 54.123 |
| Operating Margin | 2.067 |
| Pretax Margin | 6.958 |
| Net Margin | 12.026 |
| Return on Assets | 8.728 |
| Return on Equity | 15.032 |
| Return on Total Capital | 12.34 |
| Return on Invested Capital | 14.242 |
HCM Capital Structure
| Total Debt to Total Equity | 11.79 |
| Total Debt to Total Capital | 10.547 |
| Total Debt to Total Assets | 6.73 |
| Long-Term Debt to Equity | 6.988 |
| Long-Term Debt to Total Capital | 6.251 |